Skip to main content
Premium Trial:

Request an Annual Quote

Nothing to Worry About?

Conflicts of interest in pharma have been an area of concern for many people, both inside and outside of the industry, says Pharmalot's Ed Silverman. However, one expert says we may have gone too far, and that efforts to prevent conflicts could even hurt patients. Richard Epstein, NYU law professor and a visiting scholar at the Manhattan Institute, an economics think tank, says that responses to the perceived threat of conflicts of interest have been "wildly disproportionate" to the magnitude of the actual problem." For example, Epstein says, FDA disclosure rules have emptied "nearly one-third" of its advisory panel seats, and NIH's rule forbidding its researchers from communicating with their private-sector colleagues "stifles innovation."

But, Pharmalot's Silverman says that not everyone agrees. The University of Pennsylvania's bioethicist Art Caplan suggests that Epstein's notions have more to do with politics and a conservative, anti-regulatory stance, than with actual problems in conflicts of interest policies.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.